Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN2 | P17706 | 2/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | GAA | P10253 | 4/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL422589 | 0.86 | POLB (0.57) | PTPN2HDAC3HDAC4HDAC1HDAC6 | |
| SCHEMBL261464 | 0.81 | CSNK2A2 (0.45) | PTPN2HDAC3HDAC4HDAC1HDAC6 | |
| SCHEMBL12438331 | 0.81 | ALDH1A1 (0.57) | HDAC3HDAC4HDAC1HDAC6KDM4E | |
| SCHEMBL14269800 | 0.80 | MAPT (0.37) | PTPN2HDAC3HDAC4HDAC1HDAC6 | |
| SCHEMBL6919868 | 0.79 | HDAC3 (0.43) | PTPN2HDAC3HDAC4HDAC1HDAC6 | |
| SCHEMBL8629934 | 0.79 | DAO (0.59) | HDAC3HDAC4HDAC1HDAC6KDM4E | |
| SCHEMBL10109854 | 0.79 | PTPN2 (0.49) | PTPN2HDAC3HDAC4HDAC1HDAC6 | |
| SCHEMBL3878737 | 0.78 | USP10 (0.56) | PTPN2KDM4EALDH1A1HPGDL3MBTL1 | |
| SCHEMBL2241077 | 0.77 | TSHR (0.52) | PTPN2HDAC3HDAC4HDAC1HDAC6 | |
| SCHEMBL20481990 | 0.77 | PTPN2 (0.47) | PTPN2HDAC3HDAC4HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040266796-A1 | Convergent processes for the synthesis of a GARFT inhibitor containing a methyl substituted thiophene core and intermediates therefor | AGOURON PHARMACEUTICALS, INC. | 2004-12-30 | — | — | US | disclosed |
| WO-2004113337-A1 | CONVERGENT SYNTHESIS OF A GARFT INHIBITOR CONTAINING A METHYL SUBSTITUTE THIOPHENE CORE AND A TETRAHYDROPYRIDO`2,3-D! PYRIMIDINE RING SYSTEM AND INTERMEDIATES THEREFOR | PFIZER INC. (US) | 2004-12-29 | — | — | WO | disclosed |
| EP-0846111-B1 | SYNTHESES OF OPTICALLY PURE COMPOUNDS USEFUL AS GARFT INHIBITORS AND THEIR INTERMEDIATES | AGOURON PHARMA (US) | 2003-08-27 | — | — | EP | disclosed |
| US-5981748-A | Synthesis of optically pure compounds useful as GARFT inhibitors and their intermediates | AGOURON PHARMACEUTICALS, INC. (US) | 1999-11-09 | — | — | US | disclosed |
| US-5831100-A | Syntheses of optically pure compounds useful as GARFT inhibitors and their intermediates | AGOURON PHARMACEUTICALS, INC. (US) | 1998-11-03 | — | — | US | disclosed |
| EP-0846111-A1 | SYNTHESES OF OPTICALLY PURE COMPOUNDS USEFUL AS GARFT INHIBITORS AND THEIR INTERMEDIATES | AGOURON PHARMACEUTICALS, INC. (US) | 1998-06-10 | — | — | EP | disclosed |
| WO-1996040674-A1 | SYNTHESES OF OPTICALLY PURE COMPOUNDS USEFUL AS GARFT INHIBITORS AND THEIR INTERMEDIATES | AGOURON PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266796-A1 | Convergent processes for the synthesis of a GARFT inhibitor containing a methyl substituted thiophene core and intermediates therefor | DOHH, COASY, SOAT1 | PTPN2 4578/4885HDAC3 4019/4885HDAC4 2532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.